SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is facing extreme volatility and intense community frustration following a severe earnings miss and weak forward guidance, with investors expressing shock as the stock breaks below multi-year support levels. Much of the discourse centers on a loss of confidence in leadership and the aggressive repricing of the companys growth narrative, while some traders weigh whether the steep drop offers a contrarian buying opportunity or signals a deeper structural decline.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys stock is drawing intense community focus as traders prepare for earnings, fueled by speculation surrounding a potential buyout, high short interest, and aggressive institutional accumulation. Enthusiasts are framing the setup as a coiled spring, with many actively debating whether the stock's current price levels indicate structural undervaluation or further downside potential following recent institutional activity.

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

Doximity Inc

Doximity is trending due to a sharp stock price decline following its latest earnings report, where conservative forward guidance overshadowed a top-and-bottom line beat. The community is actively debating whether this movement represents an overreaction by algorithms or a fundamental reset, with many traders focused on the stock's volatility and its potential for a short-term bounce or further downside.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened scrutiny and market volatility as investors weigh disappointing earnings results against management's maintained guidance and growth expectations for their new Predictions platform. The community remains deeply divided, with bearish voices highlighting increased competition and management concerns, while bullish investors focus on potential upside heading into the upcoming football season.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is experiencing a significant surge in momentum following strong quarterly results, with investors cheering accelerating cloud revenue and the successful integration of AI tools. The stock has become a focal point for community discussions as traders weigh whether this software rally marks a definitive end to sector-wide pessimism or serves as a tactical short-squeeze opportunity.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors weigh a strong earnings beat and raised guidance against a sharp pullback sparked by a major workforce restructuring. While the community is debating whether the layoffs signal necessary efficiency gains or broader AI-related demand concerns, many are actively positioning themselves to buy the dip, citing the company's critical role in the expanding 'Agentic Internet' infrastructure.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing heightened community skepticism following a disappointing earnings report that missed estimates, with investors increasingly frustrated by the company's reliance on projected revenue growth rather than confirmed contract wins. While some long-term bulls remain committed to the company's defense-focused drone and autonomous vessel portfolio, many are demanding immediate execution and evidence of sales to justify the current valuation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is facing extreme market volatility and investor uncertainty as it remains in a prolonged state of silence following its PDUFA date, leaving stakeholders to speculate between a potential conditional approval or a third complete response letter. Community discussion is heavily divided between frustrated bears highlighting the lack of transparency and regulatory history, and persistent bulls anticipating a favorable outcome after an advisory committee vote, while observers warn of significant dilution risks regardless of the final news.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is surging following a blowout earnings report that shattered analyst expectations, with revenue growth and margin expansion signaling strong commercial momentum for its flagship TIL therapy. The community is buzzing over management's upbeat commentary on the lung cancer pipeline and the resolution of the Replimmune competitive overhang, fueling widespread calls for a sustained rally as institutional re-evaluation begins.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is facing significant downward pressure as investors react to a double earnings miss and concerns over slowing core brand growth, fueling intense community debate regarding the company's management and future outlook. While some traders view the resulting sell-off as a long-term accumulation opportunity for a diversified energy portfolio, many community members remain skeptical, pointing to increased competition and flagging sales performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up   - Here's Why

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...

Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering

(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...

239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc

Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info